Lupin Limited has informed the Exchange about U.S. FDA has concluded an inspection at our manufacturing facility located in Somerset, New Jersey, U.S.A.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited has disclosed that the U.S. FDA completed a routine inspection at its Somerset, New Jersey manufacturing facility from April 13-17, 2026. The inspection resulted in the issuance of a Form-483 with three observations, which are FDA-issued notices listing potential violations found during the inspection. Lupin has stated it will respond to these observations within the stipulated timeframe and remains committed to complying with Current Good Manufacturing Practice (CGMP) standards across all its facilities. This is a regulatory compliance disclosure required under SEBI Listing Regulations.
Form-483 observations indicate potential regulatory compliance issues at the facility. While common in the pharmaceutical industry, three observations could lead to warning letters or import alerts if not adequately addressed, potentially affecting supply of U.S.-bound products and investor sentiment.